Vagal intimations for catatonia and electroconvulsive therapy

Journal of ECT

Volumn 30, Issue 2, 2014, Pages 111-115

  Dhossche, Dirk M ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Anticholinergic; Benzodiazepines; Catatonia; Electroconvulsive therapy; Mechanism; Vagal nerve

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE;

CATATONIA; ELECTROCONVULSIVE THERAPY; ENDOCRINE DISEASE; EPILEPSY; FEAR; GENETIC RISK; HEALTH HAZARD; IMMUNOPATHOLOGY; REVIEW; SOCIAL BEHAVIOR; VAGUS NERVE; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES; THEORETICAL MODEL;

BENZODIAZEPINES; CATATONIA; COMBINED MODALITY THERAPY; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMANS; MODELS, THEORETICAL; VAGUS NERVE;

EID: 84901616844     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000134     Document Type: Review

References (72)

1. Fink M. The intimate relationship between catatonia and convulsive therapy. J ECT. 2010;26:243-245.
2. van Waarde JA, Tuerlings JH, Verwey B, et al. Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients. J ECT. 2010;26:248-252.
3. Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137-143. (Pubitemid 26084531)
4. Consoli A, Benmiloud M, Wachtel L, et al. Electroconvulsive therapy in adolescents with the catatonia syndrome: efficacy and ethics. J ECT. 2010;26:259-265.
5. Thomas P, Rascle C, Mastain B, et al. Test for catatonia with zolpidem. Lancet. 1997;349:702. (Pubitemid 27107757)
6. Abrams R. Electroconvulsive Therapy. 4th ed. New York, NY: Oxford University Press; 2002.
7. Dhossche DM, Stoppelbein L, Rout UK. Etiopathogenesis of catatonia: generalizations and working hypotheses. J ECT. 2010;26:253-258.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed (DSM-5). Washington, DC: American Psychiatric Association; 2013.
9. Francis A, Fink M, Appiani F, et al. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J ECT. 2010;26: 246-247.
10. Dhossche D, Goetz M, Gadzag G, et al. New DSM-5 category unspecifed catatonia is a boost for pediatric catatonia. Neuropsychiatry. 2013;3:401-410.
11. Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand Suppl. 2013;441:1-47.
12. Fink M, Taylor M. Catatonia. A Clinician's Guide to Diagnosis and Treatment. Cambridge, UK: University Press; 2003.
13. Fink M. Historical article: Autobiography of L. J. Meduna. Convuls Ther. 1985;1:43-57.
14. Krishnamoorthy ES, Trimble MR, Sander JW, et al. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002;3:303-308. (Pubitemid 35256227)
15. Northoff G, Steinke R, Czcervenka C, et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry. 1999;67:445-450. (Pubitemid 29438198)
16. Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry. 1997;62:404-406. (Pubitemid 27199118)
17. Northoff G, Wenke J, Demisch L, et al. Catatonia: short-term response to lorazepam and dopaminergic metabolism. Psychopharmacol. 1995;122:182-186. (Pubitemid 26020728)
18. Rogers KJ, Slater P. Brain acetylcholine and monoamines during experimental catatonia. J Pharmacy Pharmacol. 1971;23:135-137.
19. Menza MA, Harris D. Benzodiazepines and catatonia: An overview. Biol Psychiatry. 1989;26:842-846. (Pubitemid 20016483)
20. Fricchione G, Cassem N, Hooberman D, et al. Intravenous lorazepam in neuroleptic-induced catatonia. J Clin Psychopharmacol. 1983;3: 338-342. (Pubitemid 14189697)
21. Stöber G, Seelow D, Ruschendorf F, et al. Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity. Hum Genet. 2002;111:323-330. (Pubitemid 36075058)
22. Gjessing LR. Effect of thyroxine, pyridoxine, orphenadrine-HCl, resperine and disulfiram in periodic catatonia. Acta Psychiatr Scand. 1967;43:376-384.
23. Carroll B, Goforth H. Medical catatonia. In: Caroff S, Mann S, Francis A, Fricchione G, eds. Catatonia From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Publishing, Inc; 2004.
24. McDaniel W, Spiegel D. Hyponatriemia and abnormal ingestion of water in catatonia. Primary Psychiatry. 2010;17: 29-33.
25. Raskin DE, Frank SW. Herpes encephalitis with catatonic stupor. Arch Gen Psychiatry. 1974;31:544-546.
26. Volkow ND, Harper A, Munnisteri D, et al. AIDS and catatonia. J Neurol Neurosurg Psychiatry. 1987;50:104.
27. Durrant W. Catatonia after malaria. Br Med J. 1977;2:893.
28. Breakey WR, Kala AK. Typhoid catatonia responsive to ECT. Br Med J. 1977;2:357-359. (Pubitemid 8150890)
29. Cardinal R, Shah D, Edwards C, et al. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. Br J Psychiatry. 2009;195:272.
30. Mon T, L'Ecuyer S, Farber NB, et al. The use of electroconvulsive therapy in a patient with juvenile systemic lupus erythematosus and catatonia. Lupus. 2012;21:1575-1581.
31. Elia J, Dell M, Friedman D, et al. PANDAS with catatonia: A case-report. Therapeutic response to lorazepam and plasmapheresis. J Am Acad Child Adolesc Psychiatry. 2005;44:1145-1150. (Pubitemid 41508126)
32. Dhossche D, Fink M, Shorter E, et al. Anti-NMDA receptor encephalitis versus pediatric catatonia (letter to the editor). Am J Psychiatry. 2011;168:749-750.
33. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
34. Agarwala P. Catatonia in an adolescent with anti-N-methyl-D-aspartate receptor encephalitis: successful treatment with high-dose lorazepam. Resident Journal. 2011;6:10-11.
35. Wilson JE, Shuster J, Fuchs C. Anti-NMDA receptor encephalitis in a 14-year-old female presenting as malignant catatonia: medical and psychiatric approach to treatment. Psychosomatics. 2013;54: 585-589.
36. Appu M, Noetzel M. Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate (NMDA) receptor encephalitis in a teenager : A case report. Pediatr Neurol. 2014;50:262-264.
37. Braakman HM, Moers-Hornikx VM, Arts BM, et al. Pearls and oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology. 2010;75:e44-e46.
38. Mann A, Machado NM, Liu N, et al. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: A case and review of the literature. J Neuropsychiatry Clin Neurosci. 2012;24:247-254.
39. Matsumoto T, Matsumoto K, Kobayashi T, et al. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis. Psychiatry Clin Neurosci. 2012;66:242-243.
40. Dhossche DM, Ross CA, Stoppelbein L. The role of deprivation, abuse, and trauma in pediatric catatonia without a clear medical cause. Acta Psychiatr Scand. 2012;125:25-32.
41. Kahlbaum K. Die Katatonie oder das Spannungsirresein. Berlin: Verlag August Hirshwald; 1874.
42. Perkins RJ. Catatonia: the ultimate response to fear? Aust N Z J Psychiatry. 1982;16:282-287.
43. Moskowitz AK. "Scared stiff ": catatonia as an evolutionary-based fear response. Psychol Rev. 2004;111:984-1002. (Pubitemid 39375084)
44. Gallup G, Maser J. Tonic immobility: evolutionary underpinnings of human catalepsy and catatonia. In: Maser J, Seligman M, eds. Psychopathology: Experimental Models. San Francisco, CA: Freeman; 1977: 334-357.
45. Volchan E, Souza GG, Franklin CM, et al. Is there tonic immobility in humans? Biological evidence from victims of traumatic stress. Biol Psychol. 2011;88:13-19.
46. Bush G, Fink M, Petrides G, et al. Catatonia: I: Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93:129-136. (Pubitemid 26084530)
47. Freudenreich O, McEvoy J, Goff D, et al. Catatonic coma with profound bradycardia. Psychosomatics. 2007;48:74-78. (Pubitemid 46048031)
48. Wachtel L, Griffin M, Dhossche D, et al. Electroconvulsive therapy for malignant catatonia in an autistic adolescent. Autism. 2010;14:349-358.
49. Hayashi H, Aoshima T, Otani K. Malignant catatonia with severe bronchorrhea and its response to electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:310-311. (Pubitemid 43288073)
50. Gjessing LR. A review of periodic catatonia. Biol Psychiatry. 1974;8:23-45.
51. Venables PH, Wing JK. Level of arousal and the subclassification of schizophrenia. Arch Gen Psychiatry. 1962;7:114-119.
52. Rosebush P, Mazurek M. Catatonia and its treatment. Schizophr Bull. 2010;36:239-242.
53. Fink M. Electroconvulsive therapy of anxiety disorders. In: Noyes R, Roth M, Burrows G, eds. Handbook of Anxiety. Amsterdam: Elsevier Science Publishers BV; 1990: 511-518.
54. Jacobowski NL, Heckers S, Bobo WV. Delirious mania: detection, diagnosis, and clinical management in the acute setting. J Psychiatr Pract. 2013;19:15-28.
55. Taylor M, Fink M. Melancholia. The diagnosis, pathophysiology, and treatment of depressive illness. New York: Cambridge University Press; 2006.
56. Pechtel P, Pizzagalli DA. Effects of early life stress on cognitive and affective function: An integrated review of human literature. Psychopharmacol (Berl). 2011;214:55-70.
57. Porges SW. Social engagement and attachment: A phylogenetic perspective. Ann N Y Acad Sci. 2003;1008:31-47. (Pubitemid 38265148)
58. van Westerloo DJ. The vagal immune reflex: A blessing from above. Wien Med Wochenschr. 2010;160:112-117.
59. Bonaz B, Picq C, Sinniger V, et al. Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil. 2013;25:208-221.
60. Dhossche D. Autonomic dysfunction in catatonia in autism: Implications of a vagal theory: implications of a vagal theory. Autism-Open Access. 2012;2.
61. Albucher RC, DeQuardo J, Tandon R. Treatment of catatonia with an anticholinergic agent. Biol Psychiatry. 1991;29:513-514.
62. Franz M, Gallhofer B, Kanzow WT. Treatment of catatonia with intravenous biperidene. Br J Psychiatry. 1994;164:847-848.
63. Mervaala E, Kononen M, Fohr J, et al. SPECT and neuropsychological performance in severe depression treated with ECT. J Affect Disord. 2001;66:47-58. (Pubitemid 32787045)
64. Sanacora G, Mason G, Rothman D, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003;160:577-579. (Pubitemid 41094271)
65. Lipcsey A, Kardos J, Prinz G, et al. Der Effect der electrokonvulsiven Therapie auf den GABA-Spiegel des Liquor cerebrospinalis. Psychiatr Neurol Med Psychol (Leipz). 1986;38:554-555.
66. Fink M. Convulsive Therapy: Theory and Practice. New York: Raven Press; 1979.
67. Bar KJ, Ebert A, Boettger MK, et al. Is successful electroconvulsive therapy related to stimulation of the vagal system? J Affect Disord. 2010;125: 323-329.
68. Nahshoni E, Aizenberg D, Sigler M, et al. Heart rate variability increases in elderly depressed patients who respond to electroconvulsive therapy. J Psychosom Res. 2004;56:89-94. (Pubitemid 38264337)
69. Schultz SK, Anderson EA, van de Borne P. Heart rate variability before and after treatment with electroconvulsive therapy. J Affect Disord. 1997;44:13-20. (Pubitemid 27261377)
70. Devinsky O. Effects of seizures on autonomic and cardiovascular function. Epilepsy Curr. 2004;4:43-46.
71. Lado FA, Moshe SL. How do seizures stop? Epilepsia. 2008;49: 1651-1664.
72. Ogbonnaya S, Kaliaperumal C. Vagal nerve stimulator: Evolving trends. J Nat Sci Biol Med. 2013;4:8-13.